Core Viewpoint - The company has completed the repurchase and cancellation of 14,100 restricted shares, resulting in a change in total share capital from 741,623,525 shares to 741,609,425 shares [2][10]. Summary by Sections Company Restricted Stock Incentive Plan - The company approved the 2022 Restricted Stock Incentive Plan on September 30, 2022, with a total of 11,397,600 shares granted at a price of 5.66 yuan per share [4][5]. - The plan included 70 participants, and the shares were listed on November 21, 2022 [4]. Adjustments and Approvals - On September 11, 2023, the company adjusted the performance assessment indicators of the 2022 plan, which was approved by the board and supervisory committee [5]. - The board also approved adjustments to the repurchase price of the restricted shares on November 10, 2023, setting it at 5.36 yuan per share [9]. Repurchase and Cancellation of Shares - The company repurchased and canceled a total of 37,740 shares, including 42,000 shares from a departed employee and 335,400 shares from 67 other participants [9]. - The repurchase was completed on February 5, 2025, with the remaining 14,100 shares being subject to judicial freeze [9][10]. Impact on Share Capital Structure - Following the cancellation, the structure of the company's share capital was updated, with the total number of shares now at 741,609,425 [10]. - The proportion of restricted shares remains unchanged at 23% of total shares [10]. Compliance and Future Outlook - The repurchase and cancellation of shares comply with legal regulations and will not significantly impact the company's financial status or operational results [10].
莱茵生物: 关于部分限制性股票回购注销完成的公告